TICKERNERD
Menu
ETONETONHealthcare · Drug Manufacturers - Specialty & Generic

ETON Stock Forecast: Eton Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 15 Oct 2026
$51
−2.93% on the day

The 4 Wall Street analysts covering Eton Pharmaceuticals, Inc. hold a median 12-month price target of $70 — +36.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.5B
Ticker Nerd rank
99 / 100
Median analyst target
$70
Analysts covering
4
Revenue$37.6M+98.6% y/y
Operating income$12.8M
Net income$11.6M
Free cash flow$7.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.2%
1M
−6.6%
YTD
+203.5%
1Y
+168.0%
From 52W high
−20.3%
From 52W low
+257.7%
$14
$64
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ETON stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Eton Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Value
93
Revisions
91
Quality
88
Volatility
87
Growth
87
Issuance
65
Accruals
43
Size
39

Momentum (98): The shares have been drifting up relative to others.

Accruals (43): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (39): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ETON stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ETON, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70$80Jan 26Apr 26Jul 26Oct 26ETONHigh $76Median $70Low $68

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $68Median $70High $76

The green dot is the last close — the median target sits +36.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Oct 2026HC Wainwright & Co.ReiteratesBuy$70
14 Aug 2026B. Riley SecuritiesReiteratesBuy$40 → $70
14 Aug 2026Canaccord GenuityMaintainsBuy$60 → $68
14 Aug 2026HC Wainwright & Co.MaintainsBuy$65 → $70
11 Aug 2026HC Wainwright & Co.MaintainsBuy$57 → $65
28 July 2026Craig-HallumMaintainsBuy—
28 July 2026Craig-HallumMaintainsBuy$40 → $62
17 July 2026Canaccord GenuityInitiatesBuy$60
17 July 2026Canaccord GenuityInitiatesBuy—
15 May 2026HC Wainwright & Co.MaintainsBuy$52 → $57
15 May 2026HC Wainwright & Co.MaintainsBuy—
20 Mar 2026B. Riley SecuritiesMaintainsBuy—
20 Mar 2026Craig-HallumMaintainsBuy—
20 Mar 2026HC Wainwright & Co.MaintainsBuy—
3 Mar 2026Craig-HallumMaintainsBuy—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
29 May 2025HC Wainwright & Co.MaintainsBuy—
16 May 2025B. Riley SecuritiesReiteratesBuy—
14 May 2025Craig-HallumMaintainsBuy—
19 Mar 2025B. Riley SecuritiesReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ETON appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ETON vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Oct 2026, Eton Pharmaceuticals, Inc. returned +168.0% against +16.9% for the S&P 500, dividends included.

ETON vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Jan 26Apr 26Jul 26Oct 26ETONS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ETON analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+38.6%
Analysts raising
1
Analysts cutting
0
Fundamentals

Eton Pharmaceuticals, Inc. (ETON) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
132.2×

Cheaper than 5% of US stocks

Price / sales
14.3×

Cheaper than 11% of US stocks

Price / book
32.1×

Cheaper than 3% of US stocks

EV / EBITDA
60.1×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
98.6%

Higher than 92% of US stocks

Earnings growth (YoY)
98.6%

Higher than 83% of US stocks

Gross margin
67.6%

Higher than 81% of US stocks

Operating margin
35.8%

Higher than 90% of US stocks

Net margin
12.0%

Higher than 74% of US stocks

Returns & dividend
Return on equity
36.0%

Higher than 90% of US stocks

Return on assets
11.9%

Higher than 95% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Eton Pharmaceuticals, Inc. (ETON) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Eton Pharmaceuticals, Inc. has a market value of $1.5B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 June 2026: $105.6M. The latest quarter grew 98.6% year on year.

  • Net income over the same four quarters: $12.7M, a 12.0% net margin.

  • Diluted earnings per share, trailing twelve months: $0.38.

  • Free cash flow in the twelve months to 30 June 2026: −$268K.

  • Shares outstanding: 28.3M.

  • Trailing P/E: 132.2×; forward P/E: 20.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Eton Pharmaceuticals, Inc. employs 44 people — $2.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

ETON vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ETONEton Pharmaceuticals, Inc.$1.5B
99
PAHCPhibro Animal Health Corp.$1.5B
91
PCRXPacira Biosciences, Inc.$1.5B
100
ANIPANI Pharmaceuticals, Inc.$1.6B
93
XERSXeris Biopharma Holdings, Inc.$1.8B
84
TRLVTrulieve Cannabis Corp.$1.9B
85
AMPHAmphastar Pharmaceuticals, Inc.$1.1B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Eton Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ETON news & analysis

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

GlobeNewsWire · 14 Oct 2026positive

Eton Pharmaceuticals and Aquestive Therapeutics announced an exclusive U.S. and territories licensing agreement, alongside a supply agreement, for LIBERVANT® (diazepam) buccal film, a treatment for seizure clusters in patients with epilepsy. Eton anticipates commercial availability in April 2027, subject to final FDA approval.

Why it matters — The agreement gives Eton exclusive U.S. licensing rights for LIBERVANT, with a potential commercial launch dependent on FDA approval.

ETON Stock Surges 108% in Six Months: Here's What You Need to Know

Zacks Investment Research · 7 Oct 2026positive

The item reports that Eton's sales surge, raised 2026 outlook, and expanding rare-disease portfolio are boosting confidence in its growth. Its headline notes ETON stock gained 108% over six months.

Why it matters — Eton watchers may note the reported business developments and improved outlook as factors associated with confidence in the company's growth.

Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

GlobeNewsWire · 28 Sept 2026positive

Eton Pharmaceuticals announced the U.S. commercial availability of IMPAVIDO (miltefosine) capsules, marking the launch of this rare disease treatment. The announcement was made by the Company on September 28, 2026.

Why it matters — This commercial launch brings a new product to market, potentially expanding Eton's commercial portfolio in the rare disease space.

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

GlobeNewsWire · 27 Aug 2026neutral

Eton Pharmaceuticals announced that members of its executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference, which will be held September 8-10, 2026 in Boston, MA.

Why it matters — A ETON watcher would care because the company's leadership is engaging with investors and industry participants at a major healthcare conference, offering an opportunity for direct dialogue about the company.

Three Biotech Stocks Stick Out With Their Stellar Charts

Investors Business Daily · 21 Aug 2026positive

A news item highlights three biotech stocks, each of which rose after recent earnings reports and has outperformed 97% of stocks over the past 12 months, with Eton Pharmaceuticals included among them based on its strong chart performance.

Why it matters — For Eton Pharmaceuticals watchers, the item signals that ETON is being recognized among top-performing biotech stocks with notable relative strength.

FAQ

Frequently asked questions about ETON stock

What is the ETON stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Eton Pharmaceuticals, Inc. have a median 12-month price target of $70, with estimates ranging from $68 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ETON stock a buy right now?

Of the 4 analysts covering Eton Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eton Pharmaceuticals, Inc. 99 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ETON?

As at 14 Oct 2026, Eton Pharmaceuticals, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will ETON stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +36.4% from the last close, and Ticker Nerd's factor model ranks Eton Pharmaceuticals, Inc. 99 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ETON stock forecast for 2030?

No analyst covering Eton Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ETON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $68 to $76 over the next 12 months.

How has ETON stock performed over the past year?

Eton Pharmaceuticals, Inc. returned +168.0% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eton Pharmaceuticals, Inc. do?

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare and underserved diseases.

What is the latest news on ETON?

The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film". Eton Pharmaceuticals and Aquestive Therapeutics announced an exclusive U.S. and territories licensing agreement, alongside a supply agreement, for LIBERVANT® (diazepam) buccal film, a treatment for seizure clusters in patients with epilepsy. Eton anticipates commercial availability in April 2027, subject to final FDA approval.

Company

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare and underserved diseases. Eton Pharmaceuticals, Inc. offers a commercial portfolio that includes therapies for adrenal insufficiency, severe primary IGF-1 deficiency, Wilson disease, phenylketonuria, homocystinuria, tyrosinemia type 1, and central diabetes insipidus, along with prescription products such as oral suspensions, injectable formulations, and oral solutions. The company also works across pediatric and adult care settings, supporting medications used in endocrine, metabolic, and other niche therapeutic areas. Based in Deer Park, Illinois, Eton Pharmaceuticals, Inc. plays a focused role in the rare-disease market by bringing specialized medicines to patients and healthcare providers through a mix of in-licensed products, commercial launches, and targeted product development.

CEO Mr. Sean E. Brynjelsen · 44 employees · United States · https://www.etonpharma.com